

SENTARA HEALTH PLANS

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Non-Preferred Insulins

Drug Requested: Select one from below

Rapid-acting Insulin Products		
<input type="checkbox"/> Admelog[®] (insulin lispro) vial/SoloStar [®]	<input type="checkbox"/> Apidra[®] (insulin glulisine) vial/SoloStar [®]	<input type="checkbox"/> Fiasp[®] (insulin aspart) vial/FlexTouch [®] /PenFill [®] /PumpCart [®]
<input type="checkbox"/> insulin aspart vial/cartridge/pen (Novolog ABA)	<input type="checkbox"/> insulin lispro vial/pen (Humalog ABA)	<input type="checkbox"/> insulin lispro Jr pen (Humalog Jr ABA)
<input type="checkbox"/> Novolog[®] (insulin aspart) vial/FlexPen [®] /PenFill [®]	<input type="checkbox"/> Lyumjev[®] (insulin lispro-aabc) vial/KwikPen [®]	
Regular or short-acting Insulin Products		
<input type="checkbox"/> Novolin[®] R (Regular, Human Insulin) vial/FlexPen [®]		
Intermediate-acting Insulin Products		
<input type="checkbox"/> Novolin[®] N (NPH, Human Insulin) vial/FlexPen [®]		
Long-acting Insulin Products		
<input type="checkbox"/> Basaglar[®] (insulin glargine) KwikPen [®]	<input type="checkbox"/> insulin degludec vial/pen (Tresiba ABA)	<input type="checkbox"/> insulin glargine vial/SoloStar[®] (Lantus ABA)
<input type="checkbox"/> insulin glargine SoloStar[®]/Max SoloStar[®] (Toujeo SoloStar [®] ABA)	<input type="checkbox"/> Levemir[®] vial/FlexTouch [®]	<input type="checkbox"/> Semglee[®] (insulin glargine-yfgn) vial/pen
Combination Insulin Products:		
<input type="checkbox"/> insulin aspart protamine suspension/insulin aspart mix 70/30 vial/FlexPen[®] (Novolog Mix ABA)	<input type="checkbox"/> insulin lispro 75/25 mix KwikPen[®] (Humalog Mix ABA)	<input type="checkbox"/> Novolin[®] 70/30 (70% NPH, Human Insulin Isophane Suspension & 30% Regular, Human Insulin) vial/FlexPen [®]
<input type="checkbox"/> Novolog[®] Mix 70/30 (70 % insulin aspart protamine suspension & 30% insulin aspart) vial/FlexPen [®]		

(Continued on next page)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____
Member Sentara #: _____ Date of Birth: _____
Prescriber Name: _____
Prescriber Signature: _____ Date: _____
Office Contact Name: _____
Phone Number: _____ Fax Number: _____
DEA OR NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Form/Strength: _____
Dosing Schedule: _____ Length of Therapy: _____
Diagnosis: _____ ICD Code, if applicable: _____
Weight: _____ Date: _____

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

For Novolin[®] Brand, Mix or ABA products, the following criteria must be met:

- Member has tried and failed at least **30 days** of therapy with a Humulin[®] product

For Admelog[®], Apidra[®], Fiasp[®], insulin aspart, insulin lispro, Lyumjev[®] and Novolog[®] Brand, Mix or ABA products, all the following criteria must be met:

- Member must have a **30-day trial** and failure or intolerance to brand Humalog[®]
- Provider must submit clinical chart notes or a completed MedWatch form documenting the experienced treatment failure or intolerance to brand Humalog[®]

(Continued on next page)

For Basaglar[®], insulin degludec, insulin glargine, Levemir[®] and Semglee[®] Brand or ABA products, the following criteria must be met:

- Member has tried and failed at least **30 days** of therapy with **ONE** of the following
 - Lantus[®]
 - Toujeo[®]
 - Tresiba[®]

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.